[go: up one dir, main page]

WO2015169811A3 - Molécules se liant au récepteur 2 de la chimiokine anti cxc et leurs utilisations - Google Patents

Molécules se liant au récepteur 2 de la chimiokine anti cxc et leurs utilisations Download PDF

Info

Publication number
WO2015169811A3
WO2015169811A3 PCT/EP2015/059876 EP2015059876W WO2015169811A3 WO 2015169811 A3 WO2015169811 A3 WO 2015169811A3 EP 2015059876 W EP2015059876 W EP 2015059876W WO 2015169811 A3 WO2015169811 A3 WO 2015169811A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding molecules
chemokine receptor
cxc chemokine
inflammatory diseases
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/059876
Other languages
English (en)
Other versions
WO2015169811A2 (fr
Inventor
Danielle CARROLL
Chris ROSSANT
Simon Thomas Barry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of WO2015169811A2 publication Critical patent/WO2015169811A2/fr
Publication of WO2015169811A3 publication Critical patent/WO2015169811A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une molécule se liant à l'anti-CXCR2 et leurs utilisations, en particulier dans le traitement de cancers et de maladies inflammatoires. En outre, l'invention concerne des compositions et des méthodes pour le traitement de cancers et de maladies inflammatoires.
PCT/EP2015/059876 2014-05-06 2015-05-05 Molécules se liant au récepteur 2 de la chimiokine anti cxc et leurs utilisations Ceased WO2015169811A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989218P 2014-05-06 2014-05-06
US61/989,218 2014-05-06

Publications (2)

Publication Number Publication Date
WO2015169811A2 WO2015169811A2 (fr) 2015-11-12
WO2015169811A3 true WO2015169811A3 (fr) 2016-02-04

Family

ID=53055049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/059876 Ceased WO2015169811A2 (fr) 2014-05-06 2015-05-05 Molécules se liant au récepteur 2 de la chimiokine anti cxc et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2015169811A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
EP3585816A4 (fr) * 2017-02-27 2020-12-30 Monash University Anticorps cxcr2 et leurs utilisations
JP2021131228A (ja) * 2018-04-27 2021-09-09 国立大学法人 東京大学 難治性喘息の予防又は治療剤をスクリーニングする方法、及び難治性喘息の予防又は治療剤
EP3830124A1 (fr) 2018-08-01 2021-06-09 Cephalon, Inc. Anticorps anti-cxcr2 et leurs utilisations
KR20210113173A (ko) * 2018-11-12 2021-09-15 아프타리온 바이오테크 아게 Cxcl8 결합 핵산

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AIHUA LI ET AL: "Autocrine Role of Interleukin-8 in Induction of Endothelial Cell Proliferation, Survival, Migration and MMP-2 Production and Angiogenesis", ANGIOGENESIS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 8, no. 1, 1 March 2005 (2005-03-01), pages 63 - 71, XP019226901, ISSN: 1573-7209, DOI: 10.1007/S10456-005-5208-4 *
GLYNN P C ET AL: "The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis", PULMORNARY PHARMACOLOGY & THERAPEUTICS, ACADEMIC PRESS, GB, vol. 15, no. 2, 1 May 2002 (2002-05-01), pages 103 - 110, XP002552670, ISSN: 1094-5539, [retrieved on 20020629], DOI: 10.1006/PUPT.2001.0323 *
INGRID U SCHRAUFSTATTER ET AL: "IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways", AJP - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 280, 1 June 2001 (2001-06-01), United States, pages L1094 - L1103, XP055201905, Retrieved from the Internet <URL:http://ajplung.physiology.org/cgi/content/abstract/280/6/L1094> [retrieved on 20150713] *
LI A ET AL: "Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 10, 1 October 2001 (2001-10-01), pages 3298 - 3304, XP002444070, ISSN: 1078-0432 *
ROSSANT CHRISTINE J ET AL: "Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes", MABS, vol. 6, no. 6, December 2014 (2014-12-01), pages 1425 - 1438, XP009185346 *
S. CHAKRABARTI: "Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 78, no. 1, 13 April 2005 (2005-04-13), pages 279 - 288, XP055201910, ISSN: 0741-5400, DOI: 10.1189/jlb.1004612 *
THOMAS JAMIESON ET AL: "Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 9, 4 September 2012 (2012-09-04), pages 3127 - 3144, XP055201865, ISSN: 0021-9738, DOI: 10.1172/JCI61067 *

Also Published As

Publication number Publication date
WO2015169811A2 (fr) 2015-11-12

Similar Documents

Publication Publication Date Title
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
WO2016144728A3 (fr) Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer
MX2016016881A (es) Anticuerpos que se unen a axl.
IL253979B (en) Methods, preparations and kits for cancer treatment
WO2015066452A3 (fr) Méthodes de traitement de cancers pédiatriques
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
MY187296A (en) Antibody molecules to tim-3 and uses thereof
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2017015622A8 (fr) Protéines de liaison à gdf11 et leurs utilisations
WO2015127134A3 (fr) Anticorps anti-composant c5 de du systeme de complement
WO2017079570A3 (fr) Oligonucléotides à permutation épissage et méthodes d&#39;utilisation
WO2015058861A8 (fr) Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
PH12018500379B1 (en) Biopharmaceutical compositions
WO2014159669A3 (fr) Aptamères se liant à l&#39;il-6 et leur utilisation pour traiter ou diagnostiquer les pathologies associées à l&#39;il-6
WO2015200648A8 (fr) Utilisation de peptides qui bloquent l&#39;interaction métadhérine-snd1 pour le traitement du cancer
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
WO2015179835A3 (fr) Biomarqueurs mit et leurs méthodes d&#39;utilisation
EP3522873A4 (fr) Compositions et méthodes pour le traitement de la xérostomie
WO2015187727A3 (fr) Mammographie moléculaire
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EP3229793A4 (fr) Compositions et méthodes se rapportant au traitement de cancers, de maladies autoimmunes et de maladies neurodégénératives
EP3134733A4 (fr) Compositions et des procédés pour traiter des patients ayant des maladies à médiation immunitaire
WO2015169811A3 (fr) Molécules se liant au récepteur 2 de la chimiokine anti cxc et leurs utilisations
WO2015153997A3 (fr) Anticorps anti-notch 3 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15720989

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15720989

Country of ref document: EP

Kind code of ref document: A2